| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/23/2009 | CA2618380A1 Feed additive and uses thereof |
| 07/22/2009 | EP2081028A1 Use of a polypeptide to detect, prevent or treat a pathological state associated with a degenerative, neurological, autoimmune illness |
| 07/22/2009 | EP2080804A1 Modified cytokines for use in cancer therapy |
| 07/22/2009 | EP2080779A1 Polymeric derivative of nucleic acid metabolic antagonist |
| 07/22/2009 | EP2080765A1 Phosphonocephem Derivates, Their Production And Use |
| 07/22/2009 | EP2080764A1 Solid forms of ortataxel |
| 07/22/2009 | EP2080763A1 Crystalline form I of ortataxel |
| 07/22/2009 | EP2080761A1 Compounds |
| 07/22/2009 | EP2080760A1 Fused quinoline derivative and use thereof |
| 07/22/2009 | EP2080759A1 Gama-globin inducer |
| 07/22/2009 | EP2080757A1 Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| 07/22/2009 | EP2080751A1 Carboxylic acid derivative |
| 07/22/2009 | EP2080524A1 Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
| 07/22/2009 | EP2080516A1 Use of isothiocyanate derivatives as anti-myeloma agents |
| 07/22/2009 | EP2080515A1 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties |
| 07/22/2009 | EP2080514A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 07/22/2009 | EP2080513A1 Tetrahydropyridoethers for treatment of AMD |
| 07/22/2009 | EP2080512A1 Anti-cancer agent |
| 07/22/2009 | EP2080508A1 Dry powder formulation comprising an anticholinergic drug |
| 07/22/2009 | EP2080507A1 Pharmaceutical formulations comprising an anticholinergic drug |
| 07/22/2009 | EP2080504A2 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/22/2009 | EP2079833A1 Compositions and methods for immunotherapy |
| 07/22/2009 | EP2079824A2 Modified alkoxyglycerols |
| 07/22/2009 | EP2079760A2 Compositions and methods for the treatment of infections and tumors |
| 07/22/2009 | EP2079753A1 Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 07/22/2009 | EP2079749A2 Improved process for the preparation of (r)-(+)-4-(ethyiamino)-3,4-dihydro-2-(3- methoxypropyl)-2h-thieno[3,2-e]-l,2-thiazine-6-sulfonamide-l,l-dioxide |
| 07/22/2009 | EP2079747A1 Heterocyclic compounds useful as anabolic agents for livestock animals |
| 07/22/2009 | EP2079746A2 Imidazopyrazines as protein kinase inhibitors |
| 07/22/2009 | EP2079745A1 3-aminocarbonyi-substituted fused pyrazolo-derivatives as protein kinase modulators |
| 07/22/2009 | EP2079744A1 Imidazopyridazines as pi3k lipid kinase inhibitors |
| 07/22/2009 | EP2079743A1 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| 07/22/2009 | EP2079742A1 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| 07/22/2009 | EP2079740A2 Tricyclic heteroaryl compounds useful as inhibitors of janus kinase |
| 07/22/2009 | EP2079739A2 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| 07/22/2009 | EP2079738A2 7-azaindole derivatives as c-met kinase inhibitors |
| 07/22/2009 | EP2079737A1 Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| 07/22/2009 | EP2079736A1 Substituted triazoles useful as axl inhibitors |
| 07/22/2009 | EP2079735A1 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression. |
| 07/22/2009 | EP2079734A1 Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| 07/22/2009 | EP2079733A2 5- and 6-substituted benzimidazole thiophene compounds |
| 07/22/2009 | EP2079732A1 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
| 07/22/2009 | EP2079731A1 Novel substituted piperidyl-propane-thiols |
| 07/22/2009 | EP2079730A1 Mglur5 modulators |
| 07/22/2009 | EP2079729A1 Compounds and compositions as protein kinase inhibitors |
| 07/22/2009 | EP2079728A1 N-aryl pyrazole compounds for use against diabetes |
| 07/22/2009 | EP2079725A1 Piperidyl-propane-thiol ccr3 modulators |
| 07/22/2009 | EP2079724A2 Substituted pyridone compounds and methods of use |
| 07/22/2009 | EP2079719A1 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents |
| 07/22/2009 | EP2079715A1 Triazines and their use as inhibitors of metalloproteinases |
| 07/22/2009 | EP2079711A2 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists |
| 07/22/2009 | EP2079709A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals |
| 07/22/2009 | EP2079704A2 Therapeutic compounds |
| 07/22/2009 | EP2079703A1 Indazole derivatives useful as l-cpt1 inhibitors |
| 07/22/2009 | EP2079702A1 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases |
| 07/22/2009 | EP2079701A1 Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators |
| 07/22/2009 | EP2079700A1 18, 21-didesoxymacbecin derivatives for the treatment of cancer |
| 07/22/2009 | EP2079699A1 Quinoline derivatives |
| 07/22/2009 | EP2079698A1 Caspase inhibitors based on pyridazinone scaffold |
| 07/22/2009 | EP2079695A2 Phenylurea compounds as soluble epoxide hydrolase inhibitors |
| 07/22/2009 | EP2079693A1 Ether derivatives dual modulators of the 5-ht2a and d3 receptors |
| 07/22/2009 | EP2079691A1 Substituted indeno[1,2-b]indole derivatives as novel inhibitors of protein kinase ck2 and their use as tumour therapeutic agents, cytostatics and diagnostic aids |
| 07/22/2009 | EP2079690A2 3-aza-bicyclo[3.1.0]hexane derivatives |
| 07/22/2009 | EP2079689A2 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 07/22/2009 | EP2079688A1 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/22/2009 | EP2079683A2 Di-fluoro containing compounds as cysteine protease inhibitors |
| 07/22/2009 | EP2079681A1 N-alkylcarbonyl-d-amino hydroxyalkyl ester compounds and their use |
| 07/22/2009 | EP2079676A1 Salts of dihydroxyanthraquinone carboxylic acids and their therapeutic use |
| 07/22/2009 | EP2079529A1 Antimicrobially active composition having a content of bispyridinium alkane (octenidine dihydrochloride) |
| 07/22/2009 | EP2079485A2 Phenylpropionamide compounds and the use thereof |
| 07/22/2009 | EP2079484A2 Monitoring cancer stem cells |
| 07/22/2009 | EP2079480A2 Hcv ns3 protease inhibitors |
| 07/22/2009 | EP2079479A2 Hcv ns3 protease inhibitors |
| 07/22/2009 | EP2079476A2 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| 07/22/2009 | EP2079475A2 A sealed photovoltaic apparatus |
| 07/22/2009 | EP2079474A1 Liposome encapsulated poly-iclc method to prophylactically treat an avian influenza viral infection |
| 07/22/2009 | EP2079473A1 Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
| 07/22/2009 | EP2079472A2 High-purity large-scale preparation of stannsoporfin |
| 07/22/2009 | EP2079471A2 Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders |
| 07/22/2009 | EP2079470A2 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
| 07/22/2009 | EP2079469A2 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema |
| 07/22/2009 | EP2079468A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 07/22/2009 | EP2079467A2 Antidiabetic bicyclic compounds |
| 07/22/2009 | EP2079466A2 Substituted indole compounds |
| 07/22/2009 | EP2079465A2 Methods for treatment of cochlear and vestibular disorders |
| 07/22/2009 | EP2079464A2 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| 07/22/2009 | EP2079463A1 Crystalline forms of aliskiren hemifumarate |
| 07/22/2009 | EP2079462A2 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes |
| 07/22/2009 | EP2079461A1 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| 07/22/2009 | EP2079460A2 Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition |
| 07/22/2009 | EP2079459A2 Method of treating asthma, allergic rhinitis, and skin disorders |
| 07/22/2009 | EP2079456A2 Pharmaceutical cyclosporin compositions |
| 07/22/2009 | EP2079455A1 Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component |
| 07/22/2009 | EP2079454A2 Sugar coatings and methods therefor |
| 07/22/2009 | EP2079453A1 Robust sustained release formulations |
| 07/22/2009 | EP2079452A1 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
| 07/22/2009 | EP2079451A1 Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory |
| 07/22/2009 | EP2079450A2 Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| 07/22/2009 | EP2079449A2 Phenylalkylamino carbamate compositions |
| 07/22/2009 | EP2079443A2 Dual action, inhaled formulations providing both an immediate and sustained release profile |
| 07/22/2009 | EP2079442A2 Use of glycerophospholipids for joint lubrication |